TRIZ Biopharma Innovations and Noigel

TRIZ Biopharma Innovations and its sister company Noigel LLC are biotechnology firms focused on the development of "Dynamic Self-Adapting Medical Drugs," also referred to as "Quasi-living Drugs." By integrating the TRIZ (Theory of Inventive Problem Solving) methodology with AI-powered simulations, the company designs therapeutics that can autonomously adapt their molecular structure to a patient's specific biological environment and evolving disease states. Their lead programs include MoLRx, an antisense-based platform for multi-drug resistant cancers, and Albuvir, a broad-spectrum dynamic antiviral. The company's technology aims to overcome the limitations of static drug design, offering a new paradigm for personalized medicine across oncology, infectious diseases, and regenerative medicine.